FDA approves Leqembi Iqlik subcutaneous initiation dose for Alzheimer's disease

FDA approves subcutaneous self-injection initiation dosing for Leqembi (lecanemab), Alzheimer's anti-amyloid monoclonal antibody, delivered via autoinjector from treatment start. The approval reduces clinic visit burden and infusion centre dependency whilst maintaining biomarker and clinical efficacy equivalent to intravenous administration.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.